ExeVir ready for clinic with variant-targeting llama antibody
pharmaphorum
MARCH 9, 2021
Regeneron and Eli Lilly have already got antibody therapies on the market following emergency approvals by regulators including the FDA but pharma companies are beginning to focus on the threat posed by emerging variants. billion acquisition at the end of 2018, span out of VIB in 2001 and developed drugs based on similar technology.
Let's personalize your content